研究課題
We revealed the connection between bone dysmetabolism and cognitive impairment. Emerging evidence reports bone dysmetabolism could increase the risk of dementia, especially Alzheimer’s disease (AD). Our research showed that the serum level of osteocyte-derived sclerostin was positively associated with cognitive impairment in elderly individuals and aged mice. gain-of and loss-of-function of mice indicated osteocyte-derived sclerostin could pass through the blood-brain barrier (BBB) in aged mice to accelerate the cognitive impairment through the Lrp6/β-catenin/BACE1 pathway. Targeted decreasing the osteocyte-derived sclerostin not only improves bone formation but also alleviates cognitive decline in Alzheimer’s disease, which suggests a mutual therapeutic effect on bone and brain during AD progress. This paper has been published in Nature Metabolism (DOI:10.1038/s42255-024-00989-x).
2: おおむね順調に進展している
This paper has been published in Nature Metabolism, named as ‘Osteocyte-derived sclerostin impairs cognitive function during aging and Alzheimer’s disease progression’.Our paper has been invited to write the Research Briefing and one of my pictures in the main figures has been chosen to be the Cover Image, which was published with the paper and Research Briefing in the same volume (Volume 6 Issue 3, March 2024).
We continue to analyze other bone-derived factors (osteokines) that may play an important role in cognitive function during bone dysmetabolism. Additionally, our research on osteoimmunology suggests that bone dysmetabolism may regulate the immune system, including the T cells, B cells, etc during aging, which may further impact brain function. Thus, we plan to analyze the changes in the immune system during aging or pathogenesis conditions, which may provide a new pathway for connection the between bone dysmetabolism and cognitive decline.
すべて 2024
すべて 雑誌論文 (1件) (うち国際共著 1件、 査読あり 1件)
Nat Metab. 2024 Mar;6(3):
巻: 6 ページ: 531,549.
10.1038/s42255-024-00989-x
